ArticleEuropean journal of immunology2018
A clinically applicable adjuvant for an atherosclerosis vaccine in mice.
Article in European journal of immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- ApoB-specific CD4Frontiers in immunology · 2026Review
- Mitigating atherosclerosis: Integrating vaccines with gene targets.American heart journal plus : cardiology research and practice · 2025Review
- A nanovaccine for immune activation and prophylactic protection of atherosclerosis in mouse models.Nature communications · 2025Article
- A bibliometric analysis of vaccination against atherosclerosis.Human vaccines & immunotherapeutics · 2024Article
- Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?Biomolecules · 2024Review
- Review
- Identification of novel genes associated with atherosclerosis in Bama miniature pig.Animal models and experimental medicine · 2024Article
- Two decades of vaccine development against atherosclerosis.Nano today · 2023Article
- Deleting interleukin-10 from myeloid cells exacerbates atherosclerosis in ApoeCellular and molecular life sciences : CMLS · 2022Article
- Vaccination against Atherosclerosis: Is It Real?International journal of molecular sciences · 2022Review
- Single-cell transcriptomes and T cell receptors of vaccine-expanded apolipoprotein B-specific T cells.Frontiers in cardiovascular medicine · 2022Article
- Modulating Autoimmunity against LDL: Development of a Vaccine against Atherosclerosis.Hamostaseologie · 2021Article
- Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential.Drug delivery · 2021Review
- A single-dose, implant-based, trivalent virus-like particle vaccine against "cholesterol checkpoint" proteins.Advanced therapeutics · 2021Article
- ApoB-Specific CD4Cells · 2021Review
- Vaccination in Atherosclerosis.Cells · 2020Review
- Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.Immunological reviews · 2020Review
- Tolerogenic vaccines for the treatment of cardiovascular diseases.EBioMedicine · 2020Review
- Vaccination against atherosclerosis.Current opinion in immunology · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Vaccination with MHC-II-restricted peptides from Apolipoprotein B (ApoB) with complete and incomplete Freund's adjuvant (CFA/IFA) is known to protect mice from atherosclerosis. This vaccination induces antigen-specific IgG1 and IgG2c antibody responses and a robust CD4 T cell response in lymph nodes. However, CFA/IFA cannot be used in humans. To find a clinically applicable adjuvant, we tested the effect of vaccinating Apoe-deficient mice with ApoB peptide P6 (TGAYSNASSTESASY). In a broad screening experiment, Addavax, a squalene-based oil-in-water adjuvant similar to MF59, was the only adjuvant that showed similar efficacy as CFA/IFA. This was confirmed in a confirmation experiment for both the aortic arch and whole aorta analyzed by en face analysis after atherosclerotic lesion staining. Mechanistically, restimulated peritoneal cells from mice immunized with P6 in Addavax released significant amounts of IL-10. Unlike P6 in CFA/IFA, vaccination with P6 in Addavax did not induce any detectable IgG1 or IgG2c antibodies to P6. These data suggest that squalene-based adjuvants such as MF59 are good candidate adjuvants for developing a clinically effective atherosclerosis vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.